Determine the Optimum Application of Commonly Used Mouse Models for Immuno-Oncology Drug Discovery
Immunotherapeutics are revolutionizing cancer treatment, with a paradigm shift from direct tumor targeting to targeting the immune system. This is bringing a wide range of challenges to immunotherapy drug developers, who now need models with functional immunity to assess the full spectrum of preclinical immuno-oncology agents.
Immunocompetent murine models provide simple and cost-effective alternatives to complex humanized models. GEMM, syngeneics, and murine tumor homograft models provide a flexible assessment platform for surrogate and cross reactive agents which can cover the breadth of mechanism of action and efficacy studies needed for immunotherapy assessment.
The key to choosing the correct murine immunocompetent model for your study depends on a thorough understanding of the different model features, advantages, and drawbacks, and how these can be exploited most effectively for a comprehensive drug discovery program.
Download This White Paper to Understand:
- The main pros and cons of GEMM, syngeneic, and murine tumor homograft models
- How the type of immunocompetent mouse model used depends on the study question being asked, as well as model features such as orthotopic vs subcutaneous tumor engraftment, amenability to bioluminescent imaging, tumor stroma availability, and tumor mutational load
- How syngeneics provide an ideal platform for combination studies, and how murine homograft tumor models can be generated for highly specific disease areas/targets, as exemplified by case studies